WGN-TV

Invitae Launches its First CE-IVD Cancer Testing Kits In Europe

SAN FRANCISCO, Feb. 16, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx ® and LiquidPlex Dx ™ in Europe, part of its ...
Business Wire

Invitae Announces Major Expansion of Its Test Menu for Neurological, Pediatric, and Rare Genetic Conditions and Introduces New Panels for Inherited Metabolic Disorders and ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
Seeking Alpha

Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...
Business Wire

Invitae and TME Research Announce Landmark New Study to Evaluate Universal Genetic Testing of Breast Cancer Patients

SAN FRANCISCO-- (BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the ...
Seeking Alpha

Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing

SAN FRANCISCO, March 15, 2023 /PRNewswire/ -- Invitae (NVTA) (NYSE: NVTA), a leading medical genetics company, today announced seven studies, including one oral presentation and six posters, to be ...